Investing News NetworkYour trusted source for investing success
Helium Evolution
Integrated Cyber Solutions
Soma Gold Corp.
Nextech3D.ai
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
4 Private Longevity Research Companies (Updated 2023)
Private longevity research companies deserve investor attention as the longevity side of the life science market grows.

Longevity research companies are working to promote healthy aging and extend life expectancy.
A long, healthy life is something everyone has a vested interest in, but that doesn't mean it's always easy to get into longevity investing. Many longevity research companies remain private, meaning it's difficult for the average person to secure a stake.
However, investors shouldn't ignore private longevity research companies. They represent a potential opportunity to gain exposure to rapid growth in a sector that touches diverse life science markets. Plenty of private longevity research companies are working on innovative studies aimed at diseases associated with aging, including cardiovascular disease, type 2 diabetes and various cancers. If they do go public one day, investors who have them on their radar already will be ahead of the game.
Here's a short list of some of the top private longevity research companies making headlines today.
1. Altos Labs
Based in Los Altos, California, Altos Labs is a biotechnology company that is developing cellular rejuvenation programming to promote healthy cells in the human body and revive cells damaged by environmental stresses. The company is also establishing operations in San Diego and the UK, and is working on collaborations in Japan.
Launched after a US$3 billion investment round in early 2022, Altos Labs reportedly has the backing of big-name investors, including Amazon’s (NASDAQ:AMZN) Jeff Bezos. Altos Labs CEO Hal Barron is the former president of research and development and chief scientific officer for the pharmaceutical giant GlaxoSmithKline (LSE:GSK,NYSE:GSK).
The company has stacked its team with some of the world’s leading scientists, including: Jennifer Doudna, the co-winner of the 2020 Nobel prize in chemistry for the development of the gene-editing tool CRISPR; and Shinya Yamanaka, the winner of the 2012 Nobel prize in medicine for stem cell research. "Altos seeks to decipher the pathways of cellular rejuvenation programming to create a completely new approach to medicine, one based on the emerging concepts of cellular health," said Rick Klausner, chief scientist and founder of Altos Labs and the former director of the National Cancer Institute.
2. Retro Biosciences
Headquartered in San Francisco, Retro Biosciences is a biotechnology firm specializing in cellular reprogramming, autophagy and plasma-inspired therapeutics with a mission to increase healthy human lifespans by 10 years. “By focusing on the cellular driver of aging, Retro will produce therapeutics eventually capable of multi-disease prevention,” according to the company.
One of the newest longevity research companies, Retro has put together an all-star team headed by CEO Joe Betts-LaCroix. Betts-LaCroix was a co-founder of OQO, the company that created the then-smallest personal Windows PC in 2000; he also founded the Health Extension Foundation. Retro co-founder Sheng Ding is a professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, while co-founder Matt Buckley was formerly a systems integration engineer with life science firm Illumina, as well as a scientist with Global Biologics Development at Bayer Pharmaceuticals.
Of its three main areas of focus, Retro's cellular reprogramming work is the most advanced, and the company plans to work towards a clinical proof-of-concept over the next four years.
In April 2022, Retro Biosciences raised US$180 million in venture funding from undisclosed investors. The money is expected to take its cellular reprogramming work through clinical proof-of-concept.
3. Elevian
Biotech company Elevian is developing drugs that can restore the regenerative capacity of various tissues in the human body. These medicines have the potential to treat and prevent multiple diseases associated with aging.
While working at the Harvard Department of Stem Cell and Regenerative Biology, the company found that treatment with the circulating factor GDF11 can regenerate the heart and the brain, as well as muscle and other human tissues. Due to this discovery, Elevian has exclusive worldwide rights to Harvard's patent GDF11 portfolio.
Elevian is developing medicines that use the GDF11 pathway to target a number of age-related diseases, including strokes, diet-induced obesity, type 2 diabetes, heart failure and Alzheimer's disease. Its lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models for addressing these medical needs.
“We’re interested in proteins like GDF11 that are excreted into the bloodstream because those can cause changes throughout the body,” Dr. Mark Allen, CEO of Elevian, told the New York Times. “And those are the kind of changes we want.”
4. Insilico Medicine
Hong Kong-based Insilico Medicine is a clinical-stage biotech company harnessing the power of artificial intelligence (AI), big data analysis and genomics for researching aging and developing medicines that target cancers, infectious diseases, autoimmune diseases, central nervous system diseases and age-related diseases.
Insilico's mission involves providing AI platforms that can help identify and develop new drug candidates for untreated diseases and then predict how well those treatments may perform in clinical trials. In November 2022, Insilico signed a strategic research collaboration with Sanofi (NASDAQ:SNY) worth up to US$1.2 billion, with its value depending on certain milestones being met.
The company has a large pipeline of drug candidates targeting a variety of conditions. Its most advanced program is for idiopathic pulmonary fibrosis, which is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. In January 2023, Insilico released positive top line data from this clinical trial.
"Topline data from our Phase 1 study of INS018_055 demonstrate the ability of our Pharma.AI platform to discover novel targets and design novel molecules with a high level of translatability to human biology,” stated founder and CEO Alex Zhavoronkov.
“This lead program is paving the way for a new era of drug discovery and development that utilizes next generation AI to identify novel targets and generate novel drugs to treat diseases requiring regular peroral drug administration for the entire lifetime with very high safety requirements.”
This is an updated version of an article first published by the Investing News Network in 2016.
Don't forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- Top NASDAQ Genetics Stocks | INN ›
- 10 Top Stem Cell Companies on the NASDAQ | INN ›
- 5 Gene Therapy Stocks for Investors | INN ›
- 5 Largest Genetics Stocks by Market Cap | Amgen is First | INN ... ›
- Top Anti-aging Stocks | Market CAGR of 6.1 Percent | INN - Investing ... ›
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. Working for the Investing News Network since 2008, and formerly the first managing editor of the Investing News Network, Melissa now serves as Senior INNspired Content Developer. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
How to Invest in Genetics:
How to Invest in Genetics (Updated 2023)
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2023
5 Genetic Testing Stocks (Updated 2023)
5 US Longevity Stocks to Watch
Gene Therapy Stocks: 5 Biggest Companies in 2023
Genetics Stocks: 5 Biggest Companies in 2023
4 Private Longevity Research Companies (Updated 2023)
Outlook Reports
Featured Genetics Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2040.56 | -3.75 | |
Silver | 25.06 | -0.01 | |
Copper | 3.84 | 0.00 | |
Oil | 76.11 | -0.30 | |
Heating Oil | 2.76 | -0.06 | |
Natural Gas | 2.83 | -0.01 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. Working for the Investing News Network since 2008, and formerly the first managing editor of the Investing News Network, Melissa now serves as Senior INNspired Content Developer. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
Learn about our editorial policies.